The following Blue Cross Blue Shield announcements are just a few of the company activities from this month. AMI’s annual Blue Cross Blue Shield Plans Report provides profiles on each of the 34 BSBS plans as well as the BCBSA organization.
The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced that the FDA approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS). PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven […]
BMS digital strategy has required thinking differently about the type of value-based relationships the company wants to establish
Concerto HealthAI, offers a clinical insight generation platform that employs real-world data in its analyses
Published January 3, 2016 in Managed Healthcare Executive Is an HIV Vaccine on the horizon? There’s good news in efforts to combat HIV/AIDs and hepatitis C (hep C, HCV). These viral diseases are now more vulnerable because of improved gene-based targeting and communications around exposure from surveillance programs. Some feel, however, that policymakers could do […]
The cost and time commitment to develop new drugs has increased significantly over the last few decades. A variety of factors come into play, but on average, in terms of total expenditures, it has taken from $3 to $5 billion and up to 15 years to bring a new drug to market. Even after all […]